-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Tag Archives: Pulmonary Toxicity
Adcetris (brentuximab vedotin) Drug Safety Communication
Translation Adcetris (brentuximab vedotin): Drug Safety Communication – Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity AUDIENCE: Oncology, Hematology, Neurology ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result … Continue reading
Posted in FDA 2011, FDA Label Change, FDA Notice, FDA Warning, Hematology, Neurology, Oncology
Tagged Adcetris, Adcetris (brentuximab vedotin) Drug Safety Communication, brentuximab vedotin, drug risks, Drug Safety Communication, FDA notice, FDA warning, Progressive Multifocal Leukoencephalopathy, Pulmonary Toxicity, safety label changes
Comments Off